Aegerion Pharmaceuticals, Inc. 4
4 · Aegerion Pharmaceuticals, Inc. · Filed Mar 5, 2014
Insider Transaction Report
Form 4
Fitzpatrick Mark J.
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2014-03-04$17.64/sh+2,500$44,100→ 8,350 total - Exercise/Conversion
Stock Option (right to buy)
2014-03-04−2,500→ 189,650 totalExercise: $17.64Exp: 2021-06-01→ Common Stock (2,500 underlying)
Footnotes (1)
- [F1]132,000 of the shares of common stock underlying this stock option vest over four years in equal monthly installments starting on June 1, 2011. 88,000 of the shares of common stock underlying this stock option vest over four years in equal monthly installments starting on the date of marketing approval for JUXTAPID? (lomitapide) by the U.S. Food and Drug Administration.